Liver Cancer Drugs Market Size to grow by USD 3287 million between 2024-2028
According to a research report “ Liver Cancer Drugs Market” by Type (Immunotherapy, Targeted therapy) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 3287 million, at a CAGR of 10.03% during the forecast period. Liver cancer is a significant health concern globally, accounting for a substantial number of cancer-related fatalities. Risk factors such as hepatitis B and C infections and underlying cirrhosis contribute to the rising incidence of liver cancer. In the US, approximately 50% of liver cancer patients are diagnosed with hepatitis C, while 15% carry hepatitis B. Annually, around 31,000 Americans are diagnosed with primary liver cancer, according to ASCO data. By 2023, this number is projected to increase to 41,210 new cases, with 27,980 men and 13,230 women affected. These statistics underscore the growing demand for effective liver cancer treatments and drugs in the healthcare industry.
Browse market data tables, figures, and in-depth TOC on “Liver Cancer Drugs Market” by Type (Immunotherapy, Targeted therapy) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample
By Type, the Immunotherapy segment is projected to dominate the market size in 2024
ai_market_segmentation_by
By Geography, North America segment is expected to hold the largest market size for the year 2024
The liver cancer drugs market represents a significant business opportunity due to the rising prevalence of this malignancy worldwide. Key players in this sector are investing heavily in research and development to bring innovative therapies to market. These include targeted therapies, immunotherapies, and chemotherapies. Market growth is driven by increasing incidence rates, improving survival rates, and expanding patient populations. Strategic collaborations and partnerships are also shaping the competitive landscape.
North America is forecasted to hold the largest market size by region in 2024
The liver cancer drugs market represents a significant business opportunity due to the rising prevalence of this malignancy and the increasing demand for effective treatments. Key players in this sector are investing heavily in research and development to bring innovative therapies to market. These include targeted therapies, immunotherapies, and chemotherapies. Market growth is driven by factors such as an aging population, increasing incidence of risk factors, and improving healthcare infrastructure. Despite challenges, the future looks promising for the liver cancer drugs market.
The Liver Cancer Drugs Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
Liver cancer, also known as hepatic cancer, is a malignant growth in the liver, primarily consisting of hepatocellular carcinoma (HCC) and intrahepatic bile duct carcinoma. HCC affects both men and women, with the geriatric population and those with lifestyle practices such as heavy alcohol consumption and smoking being at higher risk. Hepatitis C and B infections, chronic hepatitis, and liver cirrhosis are significant risk factors. The drug development pipeline for liver cancer includes genome-targeted therapies and immunotherapies. Novel drugs, such as sorafenib, lenvatinib, and regorafenib, are used for treating advanced HCC. Immunotherapy, including checkpoint inhibitors, is also showing promise. Public health authorities emphasize early diagnosis, which can significantly improve the 5-year survival rate. However, liver cancer is the third leading cause of cancer deaths, with over 800,000 deaths annually. Public awareness campaigns are essential to reduce the number of deaths from this disease. Liver cancer can also manifest as intrahepatic carcinoma, hepatoblastoma, or metastatic cancer. Medications like metformin and statins have shown potential in preventing liver cancer. The liver tissues are susceptible to malignant cells, making early detection and effective treatment crucial. In conclusion, liver cancer is a significant health concern, with a high mortality rate. The drug development pipeline includes genome-targeted therapies, immunotherapies, and medications for prevention. Public awareness, early diagnosis, and effective treatment are essential to reduce the number of deaths from this disease.
Market Research Overview
The Liver Cancer Drugs Market is experiencing significant growth due to the increasing prevalence of liver cancer, driven by factors such as an aging population, lifestyle practices like excessive alcohol consumption and obesity, and the rise of non-alcoholic steatohepatitis (NASH). Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, affecting both men and women, with cirrhosis and viral hepatitis infections being major risk factors. The market is witnessing a surge in drug development, with a focus on chemotherapeutic medications, targeted therapy, genome-targeted therapy, and immunotherapy. Notable drugs include Ramucirumab, Regorafenib, Lenvatinib, and Sorafenib. However, challenges remain, such as the low response rate to current treatments, unsafe injection practices, and the need for improved screening criteria for early diagnosis. Public health authorities are emphasizing the importance of vaccination programs for viral hepatitis treatment, as well as lifestyle modifications to prevent liver inflammation and excess fat production in the liver. The drug development pipeline is rich with novel drugs, including those for intrahepatic bile duct cancer and hepatoblastoma. Elsevier reports that liver cancer is the third leading cause of cancer deaths, with HCC accounting for 90% of cases. The 5-year survival rate for liver cancer is relatively low, highlighting the need for effective treatments and early diagnosis. Factors such as liver cirrhosis, type 2 diabetes, and metastatic cancer complicate the treatment landscape, requiring a multimodal approach that may include radiation therapy, ablation, liver transplantation, and hepatectomy. The market is expected to continue growing as new treatments and diagnostic tools are developed, and public awareness of liver cancer and its risk factors increases.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
